Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Fee Schedule Blanks On Next-Gen Sequencing

This article was originally published in The Gray Sheet

Executive Summary

Labs and test makers say they are confused about what if anything Medicare contractors are paying for various molecular diagnostics including next-generation sequencing following CMS' recent release of codes and pricing for 2015. Meanwhile, industry groups are anxious that the agency has yet to issue a proposed rule to implement broader statutory changes to diagnostic price-setting.

You may also be interested in...

'Moonshot' Opportunities: Dx Reimbursement, Radiation Therapy Among Medtech Focal Points

Personalized-medicine advocates say Vice President Biden's "Cancer Moonshot" initiative is a great opportunity, but it should be putting more focus on the importance of Medicare policies in driving cancer innovation. There is also a push in the medtech space to raise the profile of radiation therapy as a central tool for treating cancer.

New CMS Lab Test Panel Meets To Make Payment Policy Recommendations

The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests held its inaugural meeting Aug. 26 to begin work on recommending crosswalks and gapfills for more than 25 molecular tests codes.

Medicare Dx Payment System Will Be Market-Based, More Transparent Under New Law

A new law makes vast changes to how clinical laboratory tests will be reimbursed by Medicare over the long term. Although the changes ultimately may lead to payment reductions, both test kits makers and laboratories applaud the new provisions. Reimbursement will better reflect the value that lab tests bring to the health care system, they say.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts